IndieBio

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Pannex Therapeutics is a scientifically-based pharmaceutical company that develops new drugs to treat chronic musculoskeletal pain. was founded in 2020.

Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Solving gout using engineered probiotics

Solving gout using engineered probiotics

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Pyrone Systems develops biopesticides that combine biology with chemistry. The company was founded in 2021.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Pyrone Systems develops biopesticides that combine biology with chemistry. The company was founded in 2021.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Kutanios is a biotechnology firm focused on creating new compounds for anti-aging, sun care, anti-acne, and skin cleaning items. Headwuartered in London.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Wayfinder Biosciences develops biosensors for ultra-high-throughput screening for high-value molecules. The company's PerfectPath biosensors make invisible molecules visible. These biosensors generate fluorescence based on the concentration of the desired small-molecule — allowing quantification of product titer at high-throughput using fast fluorescence measurements. Wayfinder Biosciences was established in 2021 and is headquartered in San Francisco, CA.

Wayfinder Biosciences develops biosensors for ultra-high-throughput screening for high-value molecules. The company's PerfectPath biosensors make invisible molecules visible. These biosensors generate fluorescence based on the concentration of the desired small-molecule — allowing quantification of product titer at high-throughput using fast fluorescence measurements. Wayfinder Biosciences was established in 2021 and is headquartered in San Francisco, CA.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.

Panacea Longevity is a biotechnology company aiming to replicate the health benefits of fasting. The company patent-pending fasting mimetic forumuation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast, enabling customers to have anti-inflammatory and antioxidant effects in human cells that could combat age-associated chronic inflammation and cellular damage. Panacea Longevity was established in 2020 and is based in San Francisco, CA.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on advancing precision medicine through the development of targeted therapeutics. Founded in 2016, the company utilizes a novel bioinformatics platform to identify small ribonucleic acid (sRNA) biomarkers, which are essential for uncovering disease signatures and facilitating drug discovery and repurposing. Their technology employs machine learning to achieve high accuracy in classifying patient samples, making it a valuable tool for identifying custom biomarker panels tailored to individual needs. Gatehouse Bio collaborates with leading drug developers to discover novel drug targets and develop companion diagnostics, with applications validated in areas such as cardiology, neurology, oncology, respiratory diseases, and rare diseases.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.

Allied Microbiota, LLC is a biotechnology company focused on developing microbial products and enzymes to address environmental contamination more efficiently and cost-effectively than traditional remediation methods. Originating from technology at Columbia University, the company's flagship product, PacBac, offers a microbial-based solution for the rapid reduction of stubborn soil contaminants, including poly-chlorinated biphenyls (PCBs), achieving up to 80% reduction in just days. This innovative approach presents significant cost savings—up to 80% compared to conventional remediation techniques like incineration—while effectively eliminating contaminants as a liability rather than merely relocating them. In addition to PacBac, Allied Microbiota is engaged in ongoing research and development to identify new microbial strains and create additional bio-products using advanced methodologies in synthetic biology, proteomics, and data science. By focusing on sustainable biochemicals and biological remediation methods, the company aims to transform the soil-remediation industry, which is valued at approximately $20 billion annually.

AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Synthetix is a decentralized synthetic asset issuance protocol operating on the Ethereum blockchain, designed for derivatives trading within the decentralized finance (DeFi) space. Based in Sydney, Australia, the platform enables the creation of on-chain synthetic assets and digital tokens. Synthetix offers various products, including the Synthetix Network Token (SNX), which serves as collateral for synthetic assets like sUSD and sEUR. Additionally, it provides Mintr, a decentralized application for SNX holders, and Swappr, a tool facilitating conversions between SNX and Ethereum. The platform aims to address the challenges of volatility in cryptocurrencies by allowing users to gain exposure to real-world currencies, commodities, and indices through synthetic assets, thereby ensuring liquidity and enabling peer-to-contract trading. Founded in 2018, Synthetix promotes an open and transparent ecosystem, leveraging smart contracts to enhance trading efficiency and accessibility.

Liberum Biotech is a biotechnology company focused on advancing protein manufacturing through proprietary molecular and hardware technologies. Its platform facilitates the rapid production of enzymes, therapeutics, and laboratory reagents, enabling clients to enhance speed and scalability while significantly reducing costs. By leveraging its innovative protein synthesizers, Liberum aims to democratize access to synthetic biology, ultimately transforming existing biologics manufacturing practices and making these technologies more accessible to a broader range of users.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

Cayuga Biotech is a startup developing novel hemostatic drugs and devices to reduce uncontrollable bleeding which is a leading cause of death from traumatic injuries. The company's polyphosphate-based drug accelerates the body's own clotting process to contain clotting at the injury site and thus minimize the risk of side effects. Cayuga is developing drugs for indications that treat traumatic hemorrhage as well as rare bleeding disorders.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.

Protera Biosciences, Inc. specializes in the production of protein-based food ingredients, focusing on innovative solutions to enhance food quality and safety. Founded in 2015 and located in Sunnyvale, California, the company offers a range of products including Protera Guard, a clean label protein that extends shelf life and replaces chemical preservatives, and Protera Sense, a plant-based oil that improves food texture without the use of palm oil or trans fats. Additionally, Protera provides antioxidant proteins and foaming and emulsifying proteins suitable for various applications, such as bakery products, chocolate, ice cream, and plant-based meat alternatives. Utilizing a proprietary deep learning algorithm named MADI, Protera accelerates the design and development of high-value protein products and enzymes, allowing for rapid validation and collaboration with clients to scale production effectively while addressing ethical and environmental challenges in food manufacturing.

Developing hardware for manufacturing next-generation medicines.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Developing hardware for manufacturing next-generation medicines.

Circularis Biotechnologies, Inc. is a biotechnology company established in 2014 and based in California. The company focuses on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, and T7 Variant Library, as well as services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. By improving the targeting of gene therapy and optimizing gene expression in under-researched organisms, Circularis seeks to advance the fields of gene therapy, biomanufacturing, and synthetic biology, ultimately benefiting medical practitioners and enhancing therapeutic outcomes.

Operator of a biotechnology company intended to help people live as long, and well, as possible by rapidly developing advanced longevity technologies. The company's technology biologically integrates with a host wearer for bi-directional information exchange rather than relying on hardware probes, enabling patients to get their personal stem cells.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Inflammatory disease affects us all. We looked 300 million years into our past to imagine a healthier future, beyond the limitations of today’s anti-inflammatory drugs. Lupa Bio is developing an entirely new class of safer, anti-inflammatory therapeutics based on compounds found in mothers’ milk ...because no technology today can screen like the forces of nature. ​

Michroma Corporation is a biotechnology company based in San Francisco, California, founded in 2019. The company specializes in producing natural thermostable colorants derived from filamentous fungi, aiming to replace synthetic and non-sustainable colorants commonly used in food and cosmetics. By leveraging a fermentation process and utilizing colorful fungal strains, Michroma provides a diverse array of pH-stable and heat-stable natural pigments. This innovative approach not only supports sustainability but also caters to the growing demand for vegetarian and environmentally friendly alternatives in the food industry.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

Pando Nutrition, Inc. is an animal microbiome company based in San Francisco, California, established in 2017. The company specializes in developing genetically engineered probiotics to enhance livestock health and performance while eliminating the need for antibiotics. Its innovative platform, known as Panbiotics, focuses on identifying and controlling methane emissions, thereby improving feed efficiency and profitability in livestock production. Pando Nutrition also addresses poultry health challenges, specifically targeting the pathogen Coccidiosis. By utilizing advanced biotechnology, the company creates yeast-based systems for animal feed that not only boost animal immunity but can also be tailored to produce essential amino acids and deliver other vital nutrients. This approach enables sustainable and efficient production processes, providing clients with access to affordable raw materials while contributing to the reduction of antibiotic dependence in agriculture.

Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Developing hardware for manufacturing next-generation medicines.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Antibiotic Adjuvant, Inc. develops decision support software aimed at enhancing antibiotic use in healthcare settings. Its primary product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance within healthcare facilities. The software serves various healthcare professionals by equipping administrators with tools and educational resources to optimize antibiotic use, providing physicians with relevant prescribing information, and supplying nurses with surveillance tools for infection reporting and diagnosis. Founded in 2014 and based in Gainesville, Florida, Antibiotic Adjuvant is unique in its approach, targeting 90% of physician hospital antibiotic prescriptions and facilitating automated resistance control to streamline antibiotic usage patterns.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Serenity Bioworks focuses on advancing the production and effectiveness of protein-based therapeutics and gene therapies, with a commitment to improving healthcare outcomes. The company aims to address underserved areas within the pharmaceutical industry, particularly in the treatment of conditions such as hemophilia, inherited retinal diseases, and neurodegenerative disorders. Serenity's innovative stabilization platform for biologics, known as CargoTek, enhances the long-term efficacy and safety profiles of these treatments, contributing to safer and more durable therapeutic options for patients. Through its efforts, Serenity Bioworks strives to implement pioneering ideas that benefit all stakeholders in the healthcare system.

Guided Clarity, Inc. develops and manufactures bioactive peptides, which target mitochondrial health for the aging population. The company’s products include medical food that isolates individual bioactive proteins with mitochondrial renewing properties. Guided Clarity, Inc. was founded in 2018 and is based in San Francisco, California.

11 Biomics LLC develops biological therapeutics for the cannabis industry. It offers small and large scale treatment and protection against fungal and bacterial diseases in cannabis and hemp. The company is based in Albuquerque, New Mexico.

Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Stämm Biotech, founded in 2014 and based in San Francisco, California, specializes in innovative biomanufacturing solutions for the life sciences sector. The company has developed a novel bioproduction system that integrates microfluidics, electroporation, and robotics to address the challenges of scaling in the biotech industry. Stämm's flagship product, the Bioprocessor, is an all-in-one, plug-and-play desktop unit that significantly enhances productivity, being at least 70 times more efficient than conventional bioreactors. Additionally, Stämm offers a suite of products including an automated continuous batch system for microbial growth, tools for tracking biological variations, and systems for monitoring microorganisms to convert data into actionable insights. This technological advancement positions Stämm to unlock a substantial market opportunity in biomanufacturing over the next decade.

Serenity Bioworks focuses on advancing the production and effectiveness of protein-based therapeutics and gene therapies, with a commitment to improving healthcare outcomes. The company aims to address underserved areas within the pharmaceutical industry, particularly in the treatment of conditions such as hemophilia, inherited retinal diseases, and neurodegenerative disorders. Serenity's innovative stabilization platform for biologics, known as CargoTek, enhances the long-term efficacy and safety profiles of these treatments, contributing to safer and more durable therapeutic options for patients. Through its efforts, Serenity Bioworks strives to implement pioneering ideas that benefit all stakeholders in the healthcare system.

Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

Antibiotic Adjuvant, Inc. develops decision support software aimed at enhancing antibiotic use in healthcare settings. Its primary product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance within healthcare facilities. The software serves various healthcare professionals by equipping administrators with tools and educational resources to optimize antibiotic use, providing physicians with relevant prescribing information, and supplying nurses with surveillance tools for infection reporting and diagnosis. Founded in 2014 and based in Gainesville, Florida, Antibiotic Adjuvant is unique in its approach, targeting 90% of physician hospital antibiotic prescriptions and facilitating automated resistance control to streamline antibiotic usage patterns.

Nivien Therapeutics is a Boston-based company founded in 2016 that focuses on developing innovative treatments for patients suffering from resistant cancers. The company has pioneered the creation of the first small molecule inhibitors of the Hippo signaling pathway, which are designed to enhance both chemotherapy and immunotherapy. Nivien Therapeutics is committed to advancing its unique platform that improves the efficacy of immuno-oncology and chemotherapy combinations, particularly for patients who do not respond to conventional treatments. By collaborating with top research institutes, the company aims to de-risk the transfer of technology assets and build a robust portfolio of biotechnology investments.

NEUROCARRUS INC, a biotechnology company, develops a novel drug delivery technology to disrupt pain signals without addiction-forming medications or disruption of muscular control. The company was incorporated in 2017 and is headquartered in Lincoln, Nebraska.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative gene therapies aimed at targeting tumor cells based on specific gene expression profiles. By utilizing a genetic switch to activate an apoptotic inducer, the therapies aim to eliminate cancer cells while preserving healthy tissue. Founded in 2016 and located in Mill Valley, California, the company is dedicated to advancing personalized medicine, particularly in the treatment of cancer and genetic disorders. Onconetics combines established gene therapy techniques with cutting-edge research to create novel treatments that seek to minimize the invasiveness, cost, and uncertainty associated with traditional cancer therapies. The goal is to develop simpler and more versatile personalized therapies that maintain patient quality of life and enhance understanding of genetic conditions.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Proteorex Therapeutics Inc. is a biotechnology company focused on developing novel therapeutics for diseases that have significant unmet medical needs. Established in 2014 and headquartered in Toronto, Canada, the company specializes in the manufacture of small molecule drugs aimed at complex targets associated with challenging diseases. Proteorex utilizes a proprietary drug discovery platform that combines innovative synthesis design, computational modeling, and patient-derived cell-based screening to identify new small molecule lead compounds. This approach enables the rapid and cost-effective exploration of druggable genomic targets that have been previously deemed undruggable by conventional methodologies. Additionally, Proteorex has an office in San Francisco to support its research and development efforts.

BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Stelvio Oncology, founded in 2017 and based in San Francisco, California, specializes in developing therapeutics for glioblastoma, an aggressive form of brain cancer. The company focuses on converting glioblastoma multiforme tumor cells into healthy cells by leveraging unique epigenetic signatures associated with specific cell types. Stelvio employs advanced technologies, including microscopic imaging of epigenetic landscapes, to identify small molecules that can induce differentiation or reverse cancerous cells into benign states. This personalized approach aims to provide innovative treatment options for glioblastoma patients, combining scientific creativity with clinical expertise to advance drug therapies and precision medicine diagnostics.

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics'​ technology leverages massive gains in print speed and resolution to break the microvasculature barrier.

Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, established in 2016, that specializes in developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company employs a unique therapeutic design methodology that focuses on inhibiting protein-protein interactions and utilizes bioinformatics techniques specifically for gram-negative bacterial species. A2A Pharmaceuticals integrates computational tools and interdisciplinary approaches in its drug development process, leveraging its proprietary SCULPT™ platform to systematically design therapeutic candidates based on experimentally determined target characteristics. In addition to its research and development efforts, the company also offers consulting services to support advancements in the pharmaceutical field.

Vali Nanomedical Corporation, a biotechnology company, develops a multidrug-delivery platform technology using proprietary nanoparticles that have multilayered structures. It offers cross-linked multilamellar liposome nanoparticle technology that allows a nano-delivery of multiple chemical payloads in defined ratios to tumors. The company was founded in 2013 and is based in Los Angeles, California.

GEA Enzymes is a San Francisco-based company specializing in the production of enzymes for the food industry. The company focuses on creating designer proteins by identifying and manipulating specific enzyme activities. Their innovative enzymes are designed to reduce saturated fat levels in food products while preserving the aroma, taste, and texture that consumers expect. GEA Enzymes aims to enhance the nutritional profile of food while ensuring that the sensory qualities remain intact.

A2A Pharmaceuticals, Inc. is a biotechnology company based in New York, established in 2016, that specializes in developing innovative drugs to combat antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company employs a unique therapeutic design methodology that focuses on inhibiting protein-protein interactions and utilizes bioinformatics techniques specifically for gram-negative bacterial species. A2A Pharmaceuticals integrates computational tools and interdisciplinary approaches in its drug development process, leveraging its proprietary SCULPT™ platform to systematically design therapeutic candidates based on experimentally determined target characteristics. In addition to its research and development efforts, the company also offers consulting services to support advancements in the pharmaceutical field.

Scaled Biolabs Inc. specializes in biotech research and development, focusing on enhancing the discovery and translation of cell therapies. Founded in 2016 and based in San Francisco, the company utilizes a miniaturized lab platform that integrates microfluidics, automation, and machine learning. This innovative Cell Therapy Discovery Engine allows biotech and pharmaceutical companies to simultaneously test hundreds of parameters across thousands of experiments, facilitating insights into cell-driven biology. By streamlining the development of cell-based products and processes, Scaled Biolabs aims to simplify manufacturing and reduce time to market, ultimately improving clinical outcomes. The company is also engaged in internal development of cell therapy assets, including a program funded by CIRM that targets iPSC-derived dopaminergic neurons as a potential treatment for Parkinson’s disease.

SyntheX, Inc. is a biotechnology company that focuses on drug discovery through a unique screening platform designed to identify and design therapeutics for oncology and other biotechnological applications. Founded in 2016 and based in San Francisco, SyntheX utilizes a synthetic biology-driven approach to efficiently synthesize and identify peptides and macrocycles that disrupt specific intracellular protein-protein interactions. The company’s development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating certain cancers that evade chemotherapy through homologous recombination. By leveraging genetically engineered circuits and proprietary DNA-encoded libraries, SyntheX targets drug discovery based on synthetic lethality and oncogene addiction, with an emphasis on addressing DNA damage repair and novel cell death mechanisms.